Celia Oreja-Guevara (Vice Chair of Neurology and Head of Multiple Sclerosis Center, University Hospital San Carlos, and Professor of Neurology, University Complutense, Madrid, Spain) discusses the background and findings of her presentation entitled: Patient involvement in treatment decision-making: a sub-analysis of the ‘MS in the 21st Century international unmet needs survey’ comparing patient and healthcare professional perspectives.
1. What is the ‘MS in the 21st Century’ initiative? (0:12)
2. What was the objective of the sub analysis that you’re presenting here at EAN? How were the data collected? (1:06)
3. What did the data reveal about approaches to treatment discussions and the factors that influence treatment decisions? (2:30)
4. What impact do you hope these findings will have on treatment decision-making in the future? (4:03)
Speaker disclosure: Celia Oreja-Guevara has nothing to disclose in relation to this video interview.
‘MS in the 21st Century’ is a Merck KGaA, Darmstadt, Germany initiative involving healthcare professionals and patient advocates
Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.
Share this Video
Related Videos In Multiple Sclerosis
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]
Patrick Vermersch, EAN 2021: Tolebrutinib in Patients with Progressive Multiple Sclerosis: Phase 3 PERSEUS and HERCULES Trials
It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!